Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(4.00) per share which missed the analyst consensus estimate of $(1.57) by 154.78 percent. This is a 69.14 percent increase over losses of $(12.96) per share from the same period last year.